Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Topic Overview

Summary

Hospital-acquired pneumonia (HAP) is defined as pneumonia that develops 48 hours or more after hospital admission and was not incubating at admission. Ventilator-associated pneumonia (VAP) is a subset of HAP occurring in mechanically ventilated patients 48 hours or more after endotracheal intubation. Both represent significant causes of morbidity and mortality in hospitalized patients, particularly in intensive care units. [1,2]

The causative organisms differ substantially from community-acquired pneumonia, with predominance of gram-negative bacilli (Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli) and Staphylococcus aureus including methicillin-resistant strains (MRSA). Multidrug-resistant (MDR) organisms are increasingly common, particularly in patients with prior antibiotic exposure, prolonged hospitalization, or immunosuppression. [1,3]

Early recognition and appropriate empirical antibiotic therapy are critical for optimal outcomes. Treatment must balance the need for broad-spectrum coverage against multidrug-resistant pathogens with antimicrobial stewardship principles. Prevention strategies, particularly VAP care bundles, have demonstrated significant reductions in incidence. [4,5]

Key Facts

• Definition HAP: Pneumonia occurring ≥48 hours after hospital admission, not incubating on admission
• Definition VAP: Pneumonia occurring ≥48 hours after endotracheal intubation in mechanically ventilated patients
• Incidence: HAP affects 5-10 per 1,000 hospital admissions; VAP occurs in 10-25% of mechanically ventilated patients [6]
• Mortality: HAP mortality 20-30%; VAP mortality 20-50%, with higher rates for MDR organisms [1,7]
• Common Organisms: Pseudomonas aeruginosa, MRSA, Klebsiella, Acinetobacter, E. coli, Enterobacter
• Timing: Early-onset (less than 5 days) typically less resistant; late-onset (≥5 days) more MDR organisms
• Diagnosis: Clinical criteria (fever, leucocytosis, purulent secretions) + new/progressive radiographic infiltrates + microbiological confirmation
• Treatment: Empirical broad-spectrum antibiotics based on local resistance patterns, de-escalated per cultures
• Prevention: VAP bundles reduce incidence by 30-55% [4,5]
• Duration: 7 days for most cases; 8-14 days for non-fermenting gram-negatives or slow clinical response [1]

Clinical Pearls

Timing Matters: Early-onset HAP/VAP (less than 5 days hospitalization) usually involves more antibiotic-susceptible organisms (S. pneumoniae, H. influenzae, MSSA), while late-onset (≥5 days) has higher rates of MDR pathogens requiring broader empirical coverage.

De-escalation is Key: Initial broad-spectrum therapy is appropriate for severe HAP/VAP, but antibiotic de-escalation based on culture results and clinical response reduces resistance development and adverse effects. Review cultures at 48-72 hours.

CPIS Limitations: Clinical Pulmonary Infection Score (CPIS) has limited diagnostic accuracy. Do not rely on CPIS alone; combine clinical judgment, radiographic findings, and microbiological data. [1]

BAL Threshold: Quantitative bronchoalveolar lavage (BAL) with threshold ≥10⁴ CFU/mL or protected specimen brush ≥10³ CFU/mL improves diagnostic specificity compared to qualitative tracheal aspirates, though outcomes may not differ. [8]

Procalcitonin Role: Procalcitonin-guided antibiotic discontinuation can safely reduce treatment duration in HAP/VAP when serial values are declining and clinical improvement is evident. [9]

MDR Risk Factors: Prior IV antibiotics within 90 days, septic shock at presentation, ARDS before VAP, ≥5 days hospitalization before pneumonia, and renal replacement therapy all increase MDR risk. [1,3]

Why This Matters Clinically

HAP and VAP are among the most common hospital-acquired infections, with VAP being the leading cause of death from healthcare-associated infections. The attributable mortality of VAP ranges from 5-13%, though crude mortality is much higher due to underlying critical illness. [7] Early appropriate antibiotic therapy—defined as antibiotics active against the causative pathogen initiated within 24-48 hours—significantly reduces mortality. Conversely, inappropriate initial therapy increases mortality by up to 2-3 fold.

The rising prevalence of multidrug-resistant organisms complicates management. Local antibiogram data must guide empirical therapy choices. Prevention through evidence-based care bundles is cost-effective and dramatically reduces VAP incidence, making prevention strategies as clinically important as treatment protocols.

---

Visual Summary

Visual assets to be added:

• HAP vs VAP diagnostic criteria flowchart
• Timeline: early-onset vs late-onset organism distribution
• Empirical antibiotic algorithm based on MDR risk factors
• VAP prevention bundle visual checklist
• Decision tree: when to obtain invasive respiratory samples
• Procalcitonin-guided therapy discontinuation algorithm

---

Epidemiology

Incidence and Prevalence

Hospital-Acquired Pneumonia (HAP):

• Incidence: 5-10 cases per 1,000 hospital admissions [6]
• Accounts for 22% of all healthcare-associated infections
• Second most common nosocomial infection after urinary tract infections
• Higher incidence in surgical patients (especially post-thoracic/abdominal surgery) and those with comorbidities

Ventilator-Associated Pneumonia (VAP):

• Incidence: 10-25% of patients receiving mechanical ventilation > 48 hours [6]
• Daily risk: 3% per day during first 5 days of ventilation, 2% per day days 6-10, then 1% per day thereafter
• Leading cause of death among hospital-acquired infections
• Most common ICU-acquired infection
• VAP bundle implementation has reduced incidence by 30-55% in many centers [4,5]

Ventilator-Associated Events (VAE):

• Broader surveillance category introduced by CDC
• Includes ventilator-associated conditions (VAC), infection-related VAC (IVAC), and possible/probable VAP
• More objective than traditional clinical VAP definitions

Mortality

HAP Mortality:

• Crude mortality: 20-33% [1]
• Attributable mortality: 5-10%
• Higher in elderly, immunocompromised, those with bacteremia or respiratory failure

VAP Mortality:

• Crude mortality: 20-50% [1,7]
• Attributable mortality: 5-13% in meta-analyses [7]
• Mortality increased with:
  • "MDR organisms (Pseudomonas, Acinetobacter, MRSA): up to 70%"
  • "Inappropriate initial antibiotic therapy: doubles mortality risk"
  • Bilateral infiltrates or ARDS
  • Septic shock
  • Underlying immunosuppression

Microbiological Epidemiology

Common Pathogens (Overall): [1,3]

1. Pseudomonas aeruginosa (15-25%) — most common gram-negative
2. Staphylococcus aureus (15-30%) — MRSA in 30-70% depending on region
3. Enterobacteriaceae (15-25%):
   • Klebsiella pneumoniae (including ESBL and carbapenem-resistant)
   • Escherichia coli
   • Enterobacter species
   • Serratia marcescens
4. Acinetobacter baumannii (5-15%) — highly variable by region
5. Stenotrophomonas maltophilia (3-5%)
6. Haemophilus influenzae — more common in early-onset
7. Streptococcus pneumoniae — more common in early-onset
8. Anaerobes — especially with witnessed aspiration
9. Fungi (Candida, Aspergillus) — in severely immunocompromised

Multidrug-Resistant (MDR) Organisms:

• Increasing globally; now 30-50% of HAP/VAP isolates in many centers [3]
• Defined as resistance to ≥1 agent in ≥3 antimicrobial categories
• Extensively drug-resistant (XDR): resistant to ≥1 agent in all but ≤2 categories
• Pandrug-resistant (PDR): resistant to all approved antimicrobial agents

Regional Variation:

• High MRSA prevalence: North America, Latin America, Southern/Eastern Europe
• High carbapenem-resistant Enterobacteriaceae: Mediterranean, Eastern Europe, Asia
• High MDR Pseudomonas and Acinetobacter: Asia, Middle East, Mediterranean

Risk Factors for HAP/VAP

Major Risk Factors:

Risk Factors Specifically for MDR Organisms: [1,3]

Essential to identify these to guide empirical therapy:

1. Intravenous antibiotics within 90 days (strongest predictor)
2. Septic shock at presentation
3. ARDS before VAP onset
4. Five or more days of hospitalization prior to pneumonia
5. Acute renal replacement therapy before VAP
6. Prior MDR colonization or infection
7. Immunosuppressive disease or therapy
8. High local prevalence of MDR pathogens (> 10-25% depending on organism)

Modifiable Risk Factors:

Healthcare interventions can modify these:

• Continuous sedation (vs. daily sedation interruption)
• Supine position (vs. semi-recumbent 30-45°)
• Gastric overdistention from enteral feeding
• Unplanned extubation with reintubation
• Circuit changes and ventilator manipulations
• Gastric pH modulation (PPIs, H2-blockers)
• Inadequate hand hygiene or infection control

---

Pathophysiology

Mechanisms of Infection

HAP and VAP result from failure of host defenses to clear bacteria that have gained access to normally sterile lower airways. Three key steps:

1. Bacterial Colonization

The oropharynx and upper gastrointestinal tract become colonized with hospital-acquired pathogens through:

• Environmental exposure (healthcare workers' hands, contaminated equipment)
• Antibiotic-induced disruption of normal flora
• Cross-contamination between patients
• Gastric colonization (facilitated by acid suppression with PPIs/H2-blockers)

In mechanically ventilated patients, bacterial biofilm forms on the endotracheal tube surface within hours, creating a protected reservoir resistant to antibiotics and host defenses.

2. Pathogen Entry into Lower Respiratory Tract

Four potential routes:

• Microaspiration (most common): Small-volume aspiration of oropharyngeal or gastric secretions containing bacteria. Occurs frequently even in healthy individuals but overwhelms defenses in critically ill.
• Gross aspiration: Large-volume aspiration during vomiting, tube feeding, or impaired consciousness
• Inhalation: Aerosolized bacteria from contaminated ventilator circuits, nebulizers, or respiratory equipment (less common with modern circuits)
• Hematogenous spread: Seeding from distant infection (rare)

3. Failure of Host Defenses

Normally, lower airways are protected by:

• Cough reflex (impaired by sedation, neuromuscular disease, endotracheal tube)
• Mucociliary clearance (impaired by smoking, COPD, viral infection, high FiO₂)
• Alveolar macrophages and neutrophils (impaired by malnutrition, immunosuppression, chronic disease)
• Immunoglobulins and antimicrobial peptides

In critically ill patients, multiple defense mechanisms fail simultaneously, allowing bacterial proliferation and pneumonia.

Endotracheal Tube and Biofilm

The endotracheal tube plays a central role in VAP pathogenesis:

Biofilm Formation:

• Bacterial biofilm forms on internal ETT surface within 24-48 hours
• Consists of bacteria embedded in extracellular matrix
• Highly resistant to antibiotics (up to 1,000-fold higher MIC than planktonic bacteria)
• Protected from host immune responses
• Fragments dislodge during suctioning or coughing, directly inoculating lower airways

Cuff Microaspiration:

• Subglottic secretions pool above the ETT cuff
• Microaspiration occurs through cuff folds or with cuff deflation
• Continuous microaspiration is common even with properly inflated cuffs
• Subglottic suctioning ports reduce this risk

Immune Response and Lung Injury

Once bacteria reach alveoli:

1. Recognition by alveolar macrophages via pattern recognition receptors (TLRs)
2. Cytokine release (TNF-α, IL-1, IL-6, IL-8) recruiting neutrophils
3. Neutrophil influx and activation
4. Bacterial killing but also collateral tissue damage from proteases and reactive oxygen species
5. Increased alveolar-capillary permeability → pulmonary edema
6. Ventilation/perfusion mismatch → hypoxemia
7. In severe cases, progression to ARDS

Organism-Specific Virulence

Pseudomonas aeruginosa:

• Secretes exotoxin A, elastase, phospholipase C causing tissue damage
• Forms robust biofilms
• Quorum sensing regulates virulence genes
• Intrinsic antibiotic resistance mechanisms

Staphylococcus aureus:

• Produces toxins (alpha-toxin, Panton-Valentine leukocidin)
• Forms biofilms on ETT
• MRSA strains often healthcare-associated with additional resistance

Klebsiella pneumoniae:

• Capsular polysaccharide prevents phagocytosis
• Some strains hypermucoviscous with enhanced virulence
• ESBL and carbapenemase production in resistant strains

Acinetobacter baumannii:

• Survives on surfaces for prolonged periods
• Forms biofilms
• Intrinsic resistance to many antibiotics; acquires additional resistance readily

---

Clinical Presentation

Cardinal Features

HAP/VAP should be suspected when a hospitalized patient (or ventilated patient ≥48h) develops:

Clinical Criteria (≥2 suggestive):

• New fever (≥38°C) or hypothermia (less than 36°C)
• Leucocytosis (WCC > 12 × 10⁹/L) or leucopenia (less than 4 × 10⁹/L)
• Purulent respiratory secretions (change in color, consistency, or volume)

Radiographic Criteria:

• New or progressive infiltrate on chest X-ray or CT

Microbiological Criteria (supportive):

• Positive cultures from respiratory samples

Note: No single sign or symptom is specific. Diagnosis requires integrating clinical, radiographic, and microbiological data. [1]

Symptoms

Respiratory:

• Dyspnea or increased work of breathing
• Productive cough (if not intubated)
• Pleuritic chest pain (suggests pleural involvement)
• Hemoptysis (uncommon; consider Pseudomonas, S. aureus, or pulmonary infarction)

Systemic:

• Fever, chills, rigors
• Malaise, weakness
• Confusion (especially elderly) — may be only presenting feature
• Anorexia

In Ventilated Patients:

• Often non-specific or absent due to sedation
• May present as:
  • Increased oxygen requirements
  • Increased ventilator support needed (higher PEEP, FiO₂)
  • Worsening gas exchange (P/F ratio decline)
  • Difficulty weaning from ventilator

Signs

Vital Signs:

• Fever > 38°C or hypothermia less than 36°C (latter suggests severe sepsis)
• Tachycardia > 100 bpm
• Tachypnea > 24 breaths/min (if spontaneously breathing)
• Hypotension (if septic shock)
• Hypoxemia (SpO₂ less than 90% on room air or increased O₂ requirements)

Respiratory Examination:

• Inspection: Tachypnea, use of accessory muscles, asymmetric chest expansion
• Palpation: Increased tactile vocal fremitus over consolidation
• Percussion: Dullness over consolidated area or effusion
• Auscultation:
  • Bronchial breath sounds (high-pitched, harsh)
  • Crackles (coarse inspiratory)
  • Reduced breath sounds if large effusion or collapse
  • Pleural rub (if pleuritis)

In Ventilated Patients:

• Increased peak airway pressures (if volume-controlled ventilation)
• Decreased tidal volumes (if pressure-controlled ventilation)
• Worsening compliance
• Increased purulent secretions on suctioning
• Ventilator alarms

Sepsis Signs:

• Hypotension (systolic less than 90 mmHg or MAP less than 65 mmHg)
• Mottled skin, delayed capillary refill (> 3 sec)
• Altered mental status
• Oliguria (less than 0.5 mL/kg/h)
• Metabolic acidosis, elevated lactate

Red Flags — Immediate Escalation Required

---

Clinical Examination

General Inspection

• Appearance: Unwell, distressed, dyspneic, cyanosed?
• Mental status: Alert, confused, drowsy? (Confusion common in elderly with pneumonia)
• Position: Unable to lie flat due to dyspnea?
• Respiratory distress: Accessory muscle use, nasal flaring, intercostal recession, paradoxical breathing

Vital Signs Assessment

Temperature:

• Fever > 38°C: Typical in HAP/VAP
• Hypothermia less than 36°C: Suggests severe sepsis; poor prognostic sign

Respiratory Rate:

• Tachypnea > 24/min: Sensitive marker of respiratory compromise
• Falling RR with worsening consciousness: Pre-respiratory arrest

Oxygen Saturation:

• SpO₂ less than 90% on room air: Significant hypoxemia
• Assess oxygen requirements: Note FiO₂ or L/min O₂ needed
• Calculate P/F ratio if arterial blood gas available (PaO₂/FiO₂): less than 300 indicates hypoxemia, less than 200 indicates ARDS

Heart Rate:

• Tachycardia > 100 bpm: Common in pneumonia and sepsis
• Relative bradycardia with high fever: Consider atypical organisms (less relevant in HAP/VAP)

Blood Pressure:

• Hypotension (systolic less than 90 or MAP less than 65): Septic shock
• Narrow pulse pressure: Suggests distributive shock

Respiratory Examination

Inspection:

• Respiratory rate and pattern
• Symmetry of chest expansion (asymmetric if unilateral consolidation or effusion)
• Accessory muscle use
• Cyanosis (central vs peripheral)
• Scars suggesting previous thoracic surgery

Palpation:

• Tracheal deviation (away from tension pneumothorax or towards collapse/fibrosis)
• Chest expansion reduced on affected side
• Tactile vocal fremitus increased over consolidation, reduced over effusion

Percussion:

• Dullness (stony dull) over consolidation or pleural effusion
• Resonant or hyper-resonant if pneumothorax

Auscultation:

• Bronchial breathing: High-pitched, loud inspiration and expiration with gap between; indicates consolidation
• Crackles: Coarse inspiratory crackles in pneumonia
• Reduced breath sounds: Large effusion, collapse, or pneumothorax
• Pleural rub: Creaking sound if pleuritis (less common in VAP)
• Wheeze: May indicate bronchospasm or secretions in airways

Examination of Ventilated Patient

Ventilator Settings Review:

• Mode, PEEP, FiO₂, tidal volume
• Changes in requirements suggesting worsening compliance or gas exchange

Secretions:

• Volume: Increased with infection
• Color: Purulent (yellow, green) suggests bacterial infection
• Consistency: Thick, tenacious secretions

Sedation Status:

• Assess depth; over-sedation may mask symptoms

Hemodynamic Status:

• Blood pressure, heart rate
• Urine output
• Peripheral perfusion (capillary refill, lactate)

Systemic Examination

Cardiovascular: Heart sounds (tachycardia, new murmur if endocarditis), peripheral pulses, signs of shock

Abdominal: Distention (may impair diaphragm), feeding tube position, aspiration risk

Neurological: Conscious level (AVPU or GCS), focal signs (stroke can cause aspiration)

Skin: Rash (drug reaction, vasculitis), IV line sites (source of bacteremia)

---

Investigations

Blood Tests

Procalcitonin Use in HAP/VAP: [9]

• Elevated PCT (> 0.5-1.0 ng/mL) supports bacterial pneumonia diagnosis
• Serial measurements guide antibiotic duration: discontinue when PCT falls to less than 0.5 ng/mL or less than 20% of peak value AND clinical improvement
• PCT-guided protocols safely reduce antibiotic exposure without worsening outcomes

Microbiological Investigations

Critical: Obtain samples before starting antibiotics when possible (but do not delay therapy).

Bronchoscopic vs Non-Bronchoscopic Sampling: [8]

• Quantitative cultures from BAL/PSB have higher specificity than qualitative tracheal aspirates
• Meta-analyses show no mortality difference between invasive (bronchoscopic) and non-invasive sampling strategies
• Non-invasive sampling (tracheal aspirate or mini-BAL) is more practical and widely used
• Invasive sampling may facilitate antibiotic de-escalation

Gram Stain:

• Immediate results guide initial therapy
• Predominant organism morphology (gram-positive cocci vs gram-negative rods)
• Gram stain-guided therapy may improve outcomes [10]

Culture and Susceptibility:

• Essential for de-escalation and antibiotic stewardship
• Report organisms and minimum inhibitory concentrations (MICs)
• Identify MDR, ESBL, carbapenemase producers

Additional Microbiological Tests (Selected Cases):

• MRSA PCR nasal swab: Negative predictive value ~95% for MRSA VAP; may allow MRSA coverage omission
• Legionella urinary antigen: If epidemiological risk or severe CAP-like presentation
• Fungal cultures: Immunocompromised patients
• Viral PCR panel: Immunocompromised; outbreak setting

Imaging

Chest X-Ray (CXR):

Indications:

• Essential for HAP/VAP diagnosis
• Baseline and follow-up to assess response

Findings:

• New or progressive infiltrate (lobar consolidation, patchy infiltrates, diffuse opacities)
• Cavitation suggests necrotizing pneumonia (S. aureus, Pseudomonas, Klebsiella)
• Pleural effusion (parapneumonic vs empyema)
• Bilateral infiltrates suggest severe pneumonia or ARDS

Limitations:

• Supine AP films in ICU patients have limited sensitivity
• Difficult to distinguish pneumonia from atelectasis, pulmonary edema, ARDS, hemorrhage
• Infiltrates may lag clinical presentation by 24-48h

Computed Tomography (CT) Chest:

Indications:

• CXR inconclusive but clinical suspicion high
• Suspected complications (abscess, empyema, PE)
• Immunocompromised host (different differential including fungal, atypical organisms)
• Failure to respond to therapy

Findings:

• Ground-glass opacities, consolidation
• Cavitation, abscesses
• Empyema (loculated fluid, pleural enhancement)
• Tree-in-bud opacities (small airways infection)

Ultrasound (Thoracic):

Indications:

• Bedside assessment of pleural effusion
• Guide pleural aspiration or chest drain insertion
• Lung ultrasound can detect consolidation (hepatization, air bronchograms, dynamic air bronchograms)

Advantages:

• Portable, no radiation, real-time

Clinical Pulmonary Infection Score (CPIS)

Proposed scoring system combining clinical, radiological, and microbiological criteria. [1]

Interpretation:

• Score > 6 suggests pneumonia
• Clinical utility limited: Low diagnostic accuracy; not recommended as sole diagnostic tool [1]
• May have role in clinical trials for standardization

---

Differential Diagnosis

HAP/VAP must be distinguished from other causes of fever, leucocytosis, and pulmonary infiltrates in hospitalized patients.

In Immunocompromised:

• Fungal pneumonia: Aspergillus (halo sign, air-crescent sign), Pneumocystis (ground-glass, no effusion)
• Viral pneumonia: CMV, influenza, RSV, COVID-19
• Mycobacterial: TB, atypical mycobacteria

---

Classification & Staging

By Timing of Onset

Note: Timing alone is insufficient. Assess MDR risk factors (prior antibiotics, septic shock, ARDS, etc.) which override timing. [1,3]

By Severity

Non-Severe HAP/VAP:

• Stable hemodynamics
• No respiratory failure (no high-flow O₂ or ventilation requirement)
• No sepsis

Severe HAP/VAP:

• Sepsis or septic shock
• Respiratory failure requiring intubation or high-flow oxygen
• ICU admission required
• Bilateral infiltrates or ARDS

Severity affects prognosis and may influence empirical antibiotic breadth (consider dual gram-negative coverage in severe VAP with Pseudomonas risk).

By MDR Risk

Low MDR Risk:

• No IV antibiotics in preceding 90 days
• less than 5 days hospitalization
• No immunosuppression
• Low local MDR prevalence (less than 10-25%)

High MDR Risk: [1,3]

Presence of any:

• IV antibiotics within 90 days
• Septic shock at VAP onset
• ARDS before VAP
• ≥5 days hospitalization before pneumonia
• Acute renal replacement therapy before VAP

Critical for empirical antibiotic selection.

---

Management

Principles

1. Early empirical antibiotics (within 1 hour if septic shock; within 6 hours otherwise) [1]
2. Broad-spectrum coverage based on MDR risk, local antibiogram, and severity
3. Obtain cultures before antibiotics (but do not delay therapy)
4. De-escalate based on culture results and clinical response at 48-72 hours
5. Appropriate duration (7 days for most; 8-14 days for non-fermenters or slow response) [1]
6. Source control (drain empyema, remove infected devices)
7. Supportive care (oxygen, ventilation, fluid resuscitation, nutrition)

Empirical Antibiotic Therapy

Choice depends on:

• MDR risk factors (most important) [1,3]
• Local resistance patterns (antibiogram)
• Severity (septic shock may warrant dual coverage)
• Allergy history

HAP/VAP WITHOUT MDR Risk Factors [1]

Consider:

• Early-onset (less than 5 days)
• No prior antibiotics (90 days)
• No septic shock, ARDS, or RRT
• Low local MDR prevalence

Recommended Regimens:

Duration: 7 days [1]

HAP/VAP WITH MDR Risk Factors [1,3]

MDR risk present:

• IV antibiotics within 90 days
• Septic shock at presentation
• ARDS before VAP
• ≥5 days hospitalization
• RRT before VAP
• High local MDR prevalence (> 10-25%)

Strategy: Cover Pseudomonas, other gram-negatives (including ESBL), and MRSA until cultures available.

Gram-Negative Coverage (choose ONE or TWO if severe):

Anti-pseudomonal β-lactam:

• Piperacillin-tazobactam 4.5 g IV q6h (extended infusion preferred: 4.5 g over 4 hours q8h)
• Cefepime 2 g IV q8h
• Ceftazidime 2 g IV q8h
• Meropenem 1-2 g IV q8h (if ESBL risk high or previous ESBL)
• Imipenem-cilastatin 500 mg IV q6h or 1 g IV q8h

Consider DUAL gram-negative coverage in: [1]

• Septic shock
• High risk of resistance (prior resistant Pseudomonas, high local resistance > 10%)
• Severe VAP

Second agent options:

• Aminoglycoside: Gentamicin 5-7 mg/kg IV q24h or tobramycin 5-7 mg/kg IV q24h or amikacin 15-20 mg/kg IV q24h
• Fluoroquinolone: Levofloxacin 750 mg IV q24h or ciprofloxacin 400 mg IV q8h
• Polymyxin (colistin or polymyxin B): If carbapenem-resistant organisms suspected; toxicity concerns

PLUS MRSA Coverage (if risk factors present):

MRSA risk factors:

• Prior MRSA colonization/infection
• High local MRSA prevalence (> 10-20%)
• IV drug use
• Recent antibiotics

MRSA-active agents:

• Vancomycin 15-20 mg/kg IV q8-12h (target trough 15-20 mg/L for pneumonia) — first-line
• Linezolid 600 mg IV/PO q12h — alternative; may have better lung penetration than vancomycin; concern for thrombocytopenia with prolonged use

Example Regimens for MDR Risk:

Regimen 1 (Standard):

• Piperacillin-tazobactam 4.5 g IV q6h (extended infusion)
• PLUS Vancomycin 15-20 mg/kg IV q8-12h

Regimen 2 (High ESBL Risk):

• Meropenem 1 g IV q8h
• PLUS Vancomycin 15-20 mg/kg IV q8-12h

Regimen 3 (Severe VAP/Septic Shock/High Pseudomonas Resistance):

• Piperacillin-tazobactam 4.5 g IV q6h (extended infusion)
• PLUS Amikacin 15-20 mg/kg IV q24h
• PLUS Linezolid 600 mg IV q12h

Duration: 7 days (minimum); 8-14 days if non-fermenting gram-negatives (Pseudomonas, Acinetobacter) or slow clinical response [1]

Antibiotic Optimization

Pharmacokinetic/Pharmacodynamic Principles:

• Extended/continuous infusions of β-lactams (piperacillin-tazobactam, cefepime, meropenem) improve time above MIC; may improve outcomes in critically ill [11]
• Therapeutic drug monitoring for vancomycin (target trough 15-20 mg/L), aminoglycosides (peak, trough)
• Dose adjustments for renal/hepatic impairment; obesity (weight-based dosing for vancomycin, aminoglycosides)
• Inhalational antibiotics (tobramycin, colistin, amikacin) as adjunct in VAP with MDR gram-negatives (limited evidence; reserve for refractory cases) [1]

De-Escalation Strategy

At 48-72 Hours: [1]

Review:

1. Culture results and sensitivities
2. Clinical response (fever, WCC, oxygenation, hemodynamics)
3. Biomarkers (CRP, procalcitonin trending down)

De-escalation Options:

De-escalation Benefits:

• Reduces resistance selection pressure
• Decreases adverse effects (C. difficile, nephrotoxicity, drug reactions)
• Lower costs
• Antimicrobial stewardship

Duration of Therapy

Recommended: [1]

• 7 days: Standard for most HAP/VAP cases with good clinical response
• 8-14 days: Non-fermenting gram-negatives (Pseudomonas, Acinetobacter, Stenotrophomonas) OR slow clinical response OR immunocompromised
• Shorter (less than 7 days): May be appropriate if procalcitonin-guided discontinuation AND clinical improvement [9]
• Longer (> 14 days): Complicated pneumonia (abscess, empyema, necrotizing), bacteremia with metastatic foci, immunocompromised with opportunistic pathogens

Clinical Response Criteria:

• Afebrile > 48 hours
• Hemodynamically stable
• Improving oxygenation
• Normalizing WCC
• Improving CXR (note: radiographic improvement lags clinical by days-weeks)

Procalcitonin-Guided Duration: [9]

• Safe and effective in reducing antibiotic exposure
• Stop antibiotics when PCT less than 0.5 ng/mL or less than 20% of peak AND clinical improvement
• Overrides calendar-based duration
• Requires serial PCT measurements (e.g., day 0, 3, 5, 7)

Failure to Respond to Therapy

Definition: No clinical improvement after 72 hours of appropriate antibiotics (persistent fever, worsening oxygenation, hemodynamic instability).

Approach:

1. Reassess diagnosis:

   • Is this truly pneumonia? (Consider atelectasis, ARDS, pulmonary edema, PE, drug reaction)
   • Are there non-pulmonary infection sources? (Bloodstream infection from line, C. difficile, urinary tract)

2. Repeat imaging:

   • CT chest to identify complications (abscess, empyema, cavitation)
   • Look for non-infectious causes

3. Repeat cultures:

   • Consider bronchoscopy with BAL (quantitative cultures)
   • Blood cultures
   • Pleural fluid if effusion

4. Consider resistant organisms:

   • Review susceptibilities; is current regimen adequate?
   • MDR organisms (ESBL, CRE, XDR Pseudomonas/Acinetobacter, MRSA)
   • Rare organisms (fungi, Nocardia, TB in immunocompromised)

5. Identify complications:

   • Empyema (needs drainage)
   • Lung abscess (prolonged antibiotics; surgery if large/refractory)
   • Metastatic infection (endocarditis, epidural abscess with S. aureus bacteremia)

6. Optimize antibiotics:

   • TDM for vancomycin, aminoglycosides
   • Ensure adequate dosing (consider augmented renal clearance in critically ill)

7. Infectious diseases consult

Supportive Care

Respiratory Support:

• Supplemental oxygen: Target SpO₂ 92-96% (88-92% if COPD)
• High-flow nasal oxygen or non-invasive ventilation (NIV) if hypoxemic respiratory failure and not intubated (caution: NIV failure may delay intubation; close monitoring)
• Mechanical ventilation: Invasive if severe respiratory failure, unable to protect airway, or refractory hypoxemia
  • Lung-protective ventilation if ARDS (tidal volume 6 mL/kg IBW, plateau pressure less than 30 cmH₂O)
  • Prone positioning if severe ARDS (P/F less than 150)
  • PEEP optimization

Hemodynamic Support:

• Fluid resuscitation: Initial 30 mL/kg crystalloid if septic shock (sepsis resuscitation bundle) [12]
• Vasopressors: Norepinephrine first-line if MAP less than 65 mmHg despite fluids
• Monitor: Lactate, urine output, perfusion markers

Nutritional Support:

• Early enteral nutrition preferred (within 24-48 hours if tolerated)
• Semi-recumbent positioning (30-45°) during feeding to reduce aspiration risk
• Avoid gastric overdistention
• Post-pyloric feeding if high aspiration risk or gastric intolerance

Prophylaxis:

• VTE prophylaxis: Pharmacological (LMWH or unfractionated heparin) unless contraindicated
• Stress ulcer prophylaxis: PPI or H2-blocker (though minimizing unnecessary acid suppression preferred to reduce VAP risk)

General ICU Care:

• Daily sedation interruption/light sedation
• Early mobilization when stable
• Glycemic control (target glucose less than 10 mmol/L)
• Avoid unnecessary blood transfusions (restrictive strategy unless active bleeding/ischemia)

---

Prevention of HAP/VAP

VAP Prevention Bundle

Multiple interventions combined reduce VAP incidence by 30-55%. [4,5] No single intervention sufficient; bundle approach essential.

Core Components: [4,5]

Additional Components:

• Avoid unnecessary reintubation: Plan extubation carefully; NIV or high-flow oxygen post-extubation in selected patients
• Minimize sedation: Lighten sedation; use protocols
• Early mobilization: Reduce ventilator days
• Avoid gastric overdistention: Enteral feeding protocols; post-pyloric if intolerant
• Hand hygiene: Prevent cross-contamination
• Ventilator circuit care: Do NOT routinely change circuits; change when visibly soiled or malfunctioning (routine changes increase VAP risk)
• Selective digestive decontamination (SDD) or selective oropharyngeal decontamination (SOD): Topical antibiotics to oropharynx ± gut; reduces VAP in some settings but concerns re: resistance; not universally adopted

Interventions NOT Recommended:

• Routine circuit changes
• Routine stress ulcer prophylaxis in all patients (use selectively; PPI/H2-blockers may increase VAP risk)
• Kinetic beds or continuous lateral rotation therapy (no proven benefit)

HAP Prevention (Non-Ventilated Patients)

• Early mobilization: Reduce aspiration risk
• Aspiration precautions: Upright positioning during feeding, swallow assessment, thickened fluids if dysphagia
• Chest physiotherapy: Post-operative patients
• Avoid unnecessary sedatives: Increase aspiration risk
• Minimize unnecessary antibiotics: Reduce MDR colonization
• Infection control: Hand hygiene, isolation of MDR patients, environmental cleaning

---

Complications

Pulmonary Complications

Lung Abscess:

• Cavitation ≥2 cm with air-fluid level
• More common with S. aureus, Klebsiella, Pseudomonas, anaerobes
• Treatment: Prolonged antibiotics (4-8 weeks); percutaneous/surgical drainage if > 6 cm or refractory

Empyema:

• Infected pleural fluid
• Diagnosis: Pleural fluid pH less than 7.2, glucose less than 2.2 mmol/L, LDH > 1,000 IU/L, positive Gram stain/culture
• Treatment: Antibiotics PLUS chest drain (large-bore); consider intrapleural fibrinolytics (tPA/DNase) if loculated; VATS/surgery if refractory [14]

Necrotizing Pneumonia:

• Extensive lung necrosis; multiple small cavities
• High mortality
• Often requires surgical resection

Bronchopleural Fistula:

• Communication between bronchus and pleural space
• Usually post-operative or necrotizing infection
• Persistent air leak; may need surgical repair

Acute Respiratory Distress Syndrome (ARDS):

• Bilateral infiltrates, P/F less than 300, not fully explained by cardiac failure
• Complicates severe HAP/VAP
• Treatment: Lung-protective ventilation, prone positioning, conservative fluid management [15]

Respiratory Failure:

• May require prolonged ventilation, tracheostomy

Systemic Complications

Sepsis and Septic Shock:

• Life-threatening organ dysfunction due to infection [12]
• Treatment: Early antibiotics, source control, fluid resuscitation, vasopressors

Multi-Organ Failure:

• AKI: Common; from sepsis, nephrotoxic drugs (aminoglycosides, vancomycin)
• Hepatic dysfunction
• Coagulopathy, DIC
• Encephalopathy

Bacteremia and Metastatic Infection:

• Bloodstream infection in 10-20%
• S. aureus bacteremia can seed: endocarditis, osteomyelitis, epidural abscess, septic arthritis
• Prolonged antibiotics (4-6 weeks for endocarditis, osteomyelitis)

Healthcare-Associated Complications

Prolonged Hospitalization:

• Mean increase 7-9 days for HAP, 11-13 days for VAP
• Increased costs: $40,000-60,000 per VAP episode

Ventilator Dependence:

• Prolonged ventilation increases complications (barotrauma, VAP, delirium)
• May require tracheostomy

Antimicrobial Resistance:

• Broad-spectrum antibiotics select for resistant organisms
• Clostridioides difficile infection (10-25% with broad-spectrum therapy)

Delirium and ICU-Acquired Weakness:

• Prolonged ICU stay, sedation, immobility
• Long-term functional impairment, cognitive dysfunction

---

Prognosis & Outcomes

Mortality

Hospital-Acquired Pneumonia:

• Crude mortality: 20-33% [1]
• Attributable mortality (directly caused by HAP): 5-10%
• Mortality higher with MDR organisms, septic shock, ARDS, immunosuppression

Ventilator-Associated Pneumonia:

• Crude mortality: 20-50% [1,7]
• Attributable mortality: 5-13% in systematic reviews [7]
• Varies widely by patient population, organism, ICU setting

Impact of Organism:

• Non-MDR organisms: Mortality ~15-25%
• MDR Pseudomonas: Mortality ~40-70%
• MDR Acinetobacter: Mortality ~50-70%
• MRSA: Mortality ~30-40%

Prognostic Factors

Poor Prognostic Factors:

Good Prognostic Factors:

• Early appropriate antibiotics
• Non-severe pneumonia (no sepsis, no respiratory failure)
• Susceptible organisms
• Good functional status pre-admission
• Younger age
• Early clinical response to therapy

Long-Term Outcomes

Survivors of HAP/VAP:

• Prolonged recovery: Weeks to months for full functional recovery
• ICU-acquired weakness: Common; may require prolonged rehabilitation
• Cognitive impairment: Post-ICU delirium can cause lasting cognitive deficits
• Reduced quality of life: Respiratory symptoms, exercise limitation
• Recurrent pneumonia risk: ~15-20% develop recurrent pneumonia within 1 year

Attributable Outcomes

HAP/VAP attributable to infection (vs underlying illness): [7]

• Mortality: 5-13% attributable
• ICU length of stay: +7-11 days
• Hospital length of stay: +11-13 days
• Costs: $40,000-60,000 per episode
• Ventilator days: +6-8 days

---

Evidence & Guidelines

Key International Guidelines

1. IDSA/ATS Guidelines (2016): [1]

• Kalil AC, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the IDSA and ATS. Clin Infect Dis. 2016;63(5):e61-e111.
• Key Recommendations:
  • Empirical therapy based on MDR risk factors (NOT just early vs late onset)
  • Seven days adequate for most cases
  • De-escalation based on cultures strongly encouraged
  • Procalcitonin may guide duration
  • VAP prevention bundles recommended

2. ERS/ESICM/ESCMID/ALAT Guidelines (2017): [2]

• Torres A, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J. 2017;50(3):1700582.
• European perspective; similar principles to IDSA/ATS
• Emphasis on antimicrobial stewardship, local antibiograms

3. NICE Guideline NG139 (2019): [17]

• Pneumonia (hospital-acquired): antimicrobial prescribing. UK guidance.
• Recommendations for empirical therapy based on severity and timing
• Emphasizes de-escalation and review at 48-72 hours

Landmark Studies and Meta-Analyses

Epidemiology and Mortality:

4. Melsen WG, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665-671. [PMID: 23622939] [7]

• Attributable mortality of VAP: 13% in fixed-effects, 9% random-effects
• VAP increases ICU and hospital length of stay

Prevention:

5. Martinez-Reviejo R, et al. Prevention of ventilator-associated pneumonia through care bundles: A systematic review and meta-analysis. J Intensive Med. 2023. [PMID: 38028633] [4]

• VAP bundles reduce VAP incidence by 30-55%
• Components: HOB elevation, sedation protocols, oral care, subglottic suctioning

6. Klompas M, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(8):915-936. [PMID: 25026608] [5]

• Comprehensive review of VAP prevention strategies
• Evidence-based recommendations for bundle components

Diagnosis:

7. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355(25):2619-2630. [PMID: 17182987] [8]

• Invasive (BAL/PSB) vs non-invasive (tracheal aspirate) sampling showed no mortality difference
• Invasive sampling led to more antibiotic changes

8. Yoshimura J, et al. Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With VAP: The GRACE-VAP Trial. JAMA Netw Open. 2022;5(4):e226136. [PMID: 35394515] [10]

• Gram stain-guided therapy improved clinical response and reduced antibiotic use

Antibiotic Duration:

9. Pugh R, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015;(8):CD007577. [PMID: 26301604] [18]

• Seven days non-inferior to longer courses for most VAP cases
• Non-fermenting gram-negatives may benefit from longer therapy

10. Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498. [PMID: 29025194] [9]

• Procalcitonin-guided therapy reduces antibiotic exposure without worsening mortality

Pharmacokinetics:

11. Rhodes NJ, et al. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis. Crit Care Med. 2018;46(2):236-243. [PMID: 29088001]

• Extended infusions of β-lactams may improve outcomes in critically ill

Sepsis Management:

12. Evans L, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. [PMID: 34605781]

• Sepsis bundles: antibiotics within 1 hour, fluid resuscitation, source control, vasopressors

Oral Care:

13. Klompas M, et al. The preventability of ventilator-associated events. The CDC Prevention Epicenters Wake Up and Breathe Collaborative. Am J Respir Crit Care Med. 2015;191(3):292-301. [PMID: 25369558]

• Chlorhexidine oral care reduces VAP

Empyema:

14. Rahman NM, et al. Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection (MIST2 trial). N Engl J Med. 2011;365(6):518-526. [PMID: 21830966]

• Combined tPA/DNase improves empyema drainage

ARDS:

15. ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and ARDS. N Engl J Med. 2000;342(18):1301-1308. [PMID: 10793162]

• Lung-protective ventilation (6 mL/kg) reduces mortality in ARDS

Inappropriate Therapy:

16. Kollef MH, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-474. [PMID: 10027448]

• Inappropriate antibiotics doubled mortality in ICU infections

NICE Guideline:

17. NICE. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139). 2019. Available at: https://www.nice.org.uk/guidance/ng139

Antibiotic Duration Meta-Analysis:

18. Pugh R, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015;(8):CD007577. [PMID: 26301604]

Recent Reviews:

19. Papazian L, et al. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888-906. [PMID: 32157357]

• Comprehensive contemporary review of VAP epidemiology, diagnosis, treatment, prevention

20. Metersky ML, et al. Management of Ventilator-Associated Pneumonia: Guidelines. Infect Dis Clin North Am. 2024;38(1):131-149. [PMID: 38280768]

• Updated guideline review emphasizing MDR risk stratification and antibiotic stewardship

---

Patient & Family Information

What is Hospital-Acquired Pneumonia (HAP)?

Hospital-acquired pneumonia is a lung infection that develops during a hospital stay, at least 48 hours after admission. It is different from pneumonia caught in the community because it involves different germs that are found in hospitals. These germs can sometimes be more resistant to antibiotics.

What is Ventilator-Associated Pneumonia (VAP)?

Ventilator-associated pneumonia is a lung infection that develops in patients who are on a breathing machine (ventilator). The breathing tube can make it easier for germs to reach the lungs. VAP develops at least 48 hours after the breathing tube is inserted.

Why Does HAP/VAP Happen?

When you are in hospital, especially if you are very unwell or on a breathing machine, your body's normal defenses against infection may be weakened. Hospital germs can enter the lungs through:

• Breathing them in from the environment
• Small amounts of saliva or stomach contents going into the lungs (called aspiration)
• The breathing tube (if on a ventilator)

Being on a ventilator, having surgery, being in intensive care, taking antibiotics previously, or having other serious illnesses all increase the risk.

What Are the Symptoms?

• Fever (high temperature) or feeling very cold
• New or worsening cough
• Colored phlegm (sputum)
• Breathlessness or needing more oxygen
• Feeling confused (especially in older people)
• Feeling generally unwell

If the patient is on a ventilator and sedated, the symptoms may not be obvious. Doctors will look for signs like new shadows on chest X-rays, fever, changes in oxygen levels, and increased secretions from the breathing tube.

How is HAP/VAP Diagnosed?

Doctors will:

• Listen to the chest with a stethoscope
• Take blood tests to check for infection
• Do a chest X-ray to look for pneumonia
• Take samples of phlegm or secretions from the breathing tube to identify the germ causing the infection

How is HAP/VAP Treated?

Antibiotics:

• Strong antibiotics given through a drip (intravenously) are the main treatment
• Initially, broad-spectrum antibiotics are used to cover a range of possible germs
• Once test results are available (usually 2-3 days), antibiotics may be changed or narrowed to target the specific germ
• Treatment usually lasts 7 days, sometimes longer for certain infections

Supportive Care:

• Oxygen therapy or breathing support (ventilator) if needed
• Fluids through a drip if the patient is dehydrated or has low blood pressure
• Physiotherapy to help clear secretions from the lungs
• Nutritional support to help the body fight the infection

What is the Outlook (Prognosis)?

• Most patients with HAP/VAP recover with appropriate treatment
• The outcome depends on how severe the pneumonia is, which germ caused it, whether the antibiotics are effective, and the patient's overall health
• Some patients may take weeks to fully recover, especially if they were on a ventilator for a long time
• Unfortunately, HAP/VAP can be serious, and some patients, particularly those who are very frail or have multiple medical problems, may not survive

How Can HAP/VAP Be Prevented?

Hospital staff take many precautions to prevent these infections:

• Good hand hygiene: Washing hands before and after patient contact
• Keeping the head of the bed elevated (30-45 degrees) for patients on ventilators
• Mouth care: Regular cleaning of the mouth and teeth, especially for ventilated patients
• Minimizing sedation so patients can wake up and breathe on their own sooner
• Removing the breathing tube as soon as it is safe to do so
• Encouraging early mobilization (getting out of bed) when possible

What Can Family Members Do?

• Ask questions: Don't hesitate to ask the medical team about the diagnosis, treatment, and progress
• Hand hygiene: Always wash your hands or use alcohol gel before and after visiting
• Support: Your presence and encouragement can help the patient's recovery
• Follow hospital policies: Infection control measures (like gowns or masks) protect everyone

Resources and Support

• British Lung Foundation: Information about lung infections — blf.org.uk
• NHS Pneumonia Information: nhs.uk/conditions/pneumonia
• Intensive Care Society: Information for families of ICU patients — ics.ac.uk/patients-relatives
• ICUsteps: Support for ICU patients and families — icusteps.org

---

References

Primary Guidelines

1. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. PMID: 27418577

2. Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J. 2017;50(3):1700582. PMID: 28890434

Epidemiology and Outcomes

3. Giuliano KK, Petlin A. The epidemiology and economic impact of hospital-acquired pneumonia. Am J Infect Control. 2023;51(2):A37-A42. PMID: 35732253

4. Martinez-Reviejo R, Garcia-Ael C, Seco-Hernandez E, et al. Prevention of ventilator-associated pneumonia through care bundles: A systematic review and meta-analysis. J Intensive Med. 2024;4(1):33-46. PMID: 38028633

5. Klompas M, Branson R, Eichenwald EC, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(8):915-936. PMID: 25026608

6. Giuliano KK, Baker D, Quinn B. The epidemiology of nonventilator hospital-acquired pneumonia in the United States. Am J Infect Control. 2018;46(3):322-327. PMID: 29097097

7. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665-671. PMID: 23622939

Diagnosis

8. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355(25):2619-2630. PMID: 17182987

9. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10(10):CD007498. PMID: 29025194

10. Yoshimura J, Kinoshita T, Yamakawa K, et al. Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia: The GRACE-VAP Randomized Clinical Trial. JAMA Netw Open. 2022;5(4):e226136. PMID: 35394515

Treatment

11. Rhodes NJ, Liu J, O'Donnell JN, et al. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis. Crit Care Med. 2018;46(2):236-243. PMID: 29088001

12. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. PMID: 34605781

13. Klompas M, Li L, Kleinman K, et al. The preventability of ventilator-associated events. The CDC Prevention Epicenters Wake Up and Breathe Collaborative. Am J Respir Crit Care Med. 2015;191(3):292-301. PMID: 25369558

Complications

14. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526. PMID: 21830966

15. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308. PMID: 10793162

16. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-474. PMID: 10027448

Guidelines and Reviews

17. National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139). 2019. Available at: https://www.nice.org.uk/guidance/ng139

18. Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015;(8):CD007577. PMID: 26301604

19. Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888-906. PMID: 32157357

20. Metersky ML, Kalil AC. Management of Ventilator-Associated Pneumonia: Guidelines. Infect Dis Clin North Am. 2024;38(1):131-149. PMID: 38280768

---

Examination Scenarios

MRCP PACES Station 5 — Integrated Clinical Assessment

Scenario: A 68-year-old man has been in ICU for 9 days following emergency laparotomy for perforated diverticulitis. He was extubated 3 days ago but now has developed fever (38.7°C), increased oxygen requirements (4L O₂ via nasal cannula, SpO₂ 91%), and purulent sputum. CXR shows new right lower lobe consolidation. He has received co-amoxiclav post-operatively.

Candidate Instructions: Please take a focused history, examine the respiratory system, review the investigations provided, and discuss your management plan with the examiners.

Model Answer:

History: Confirm post-operative course, antibiotics received, comorbidities (COPD, diabetes), immunosuppression, previous MRSA/resistant organisms.

Examination: Fever, tachypnea, hypoxemia, right lower zone crackles and bronchial breathing.

Investigations:

• WCC 18 × 10⁹/L, CRP 245 mg/L, creatinine normal
• CXR: Right lower lobe consolidation
• Blood cultures pending

Differential: HAP (most likely), aspiration pneumonia, atelectasis, pulmonary embolism.

Immediate Management:

• This is HAP with MDR risk factors (prior antibiotics, ≥5 days hospitalization, post-operative)
• Obtain sputum culture and repeat blood cultures
• Start empirical antibiotics covering Pseudomonas and MRSA: Piperacillin-tazobactam 4.5g IV q6h + Vancomycin 15-20 mg/kg IV q8-12h
• Supportive care: continue oxygen, fluids, physiotherapy
• Monitor: serial CRP/PCT, clinical response at 48-72h
• De-escalate antibiotics based on culture results
• Consider ITU review if deteriorates

FRCA/FFICM Viva — Critical Care

Examiner: A 55-year-old woman has been ventilated for 6 days following traumatic brain injury. She is now pyrexial with purulent tracheal secretions. How would you approach this?

Model Answer:

Differential: VAP most likely, but also consider sinusitis, line infection, C. difficile, VTE, acalculous cholecystitis.

Diagnosis of VAP:

• Clinical criteria: fever, purulent secretions, increased oxygen requirements
• Radiological: CXR/CT showing new infiltrates
• Microbiological: tracheal aspirate or BAL for culture
• Bloods: FBC, CRP, PCT, blood cultures, lactate

Risk factors: Duration of ventilation (> 5 days), TBI (aspiration risk), possible prior antibiotics.

MDR risk: Depends on prior antibiotics, local resistance patterns, septic shock, ARDS. Likely present given ventilation duration.

Empirical Antibiotics:

• Cover Pseudomonas and MRSA: Piperacillin-tazobactam + Vancomycin (or meropenem if ESBL risk)
• Consider dual gram-negative coverage if septic shock

Monitoring:

• Review cultures 48-72h and de-escalate
• Procalcitonin-guided duration (7 days typical)
• Reassess if no response: repeat imaging, bronchoscopy, complications (abscess, empyema)

Prevention:

• VAP bundle: HOB 30-45°, oral care with chlorhexidine, ETT cuff pressure > 20 cmH₂O, daily sedation hold/SBT, early extubation when safe

---

End of Document